​

Insulet (PODD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PODD Stock Forecast

Insulet (PODD) stock forecast, based on 40 Wall Street analysts, predicts a 12-month average price target of $285.00, with a high of $300.00 and a low of $270.00. This represents a 15.48% increase from the last price of $246.80.

$150 $180 $210 $240 $270 $300 High: $300 Avg: $285 Low: $270 Last Closed Price: $246.8

PODD Stock Rating

Insulet stock's rating consensus is Buy, based on 40 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 28 Buy (70.00%), 10 Hold (25.00%), 2 Sell (5.00%), and 0 Strong Sell (0.00%).

Buy
Total 40 0 2 10 28 Strong Sell Sell Hold Buy Strong Buy

PODD Price Target Upside V Benchmarks

TypeNameUpside
StockInsulet15.48%
SectorHealthcare Stocks 35.94%
IndustryMedical Device Stocks21.01%

Price Target Trends

1M3M12M
# Anlaysts--10
Avg Price Target--$248.80
Last Closing Price$246.80$246.80$246.80
Upside/Downside--0.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 256144--24
Mar, 255144--23
Feb, 255144--23
Jan, 255144--23
Dec, 245144--23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 08, 2024Marie ThibaultBTIG$270.00$268.960.39%9.40%
Nov 05, 2024Lee HambrightBernstein$300.00$241.3224.32%21.56%
Oct 14, 2024Jayson BedfordRaymond James$260.00$231.6112.26%5.35%
Sep 17, 2024Matt O'BrienPiper Sandler$285.00$233.8921.85%15.48%
Aug 27, 2024Matt O'BrienPiper Sandler$230.00$193.5218.85%-6.81%
Aug 27, 2024Steven LichtmanOppenheimer$233.00$193.5420.39%-5.59%
Aug 27, 2024Matthew TaylorJefferies$260.00$193.5434.34%5.35%
Aug 09, 2024Marie ThibaultBTIG$250.00$199.7925.13%1.30%
May 13, 2024Matt MiksicBarclays$200.00$165.9020.55%-18.96%
May 07, 2024Mike PolarkWolfe Research$200.00$176.4013.38%-18.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2025RBC CapitalOutperforminitialise
Jan 08, 2025BernsteinOutperformOutperformhold
Jan 03, 2025Cowen & Co.BuyBuyhold
Dec 30, 2024BTIGBuyBuyhold
Dec 11, 2024CitigroupBuyBuyhold
Dec 11, 2024CitigroupNeutralNeutralhold
Nov 05, 2024BernsteinOutperforminitialise
Oct 14, 2024William BlairBuyBuyhold
Oct 14, 2024Raymond JamesOutperformOutperformhold
Sep 17, 2024UBSBuyBuyhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.11$0.25$0.07$2.96$5.97----
Avg Forecast$0.32$0.13$0.42$1.99$3.21$3.93$4.95$5.96$7.30
High Forecast$0.33$0.13$0.43$2.08$3.36$4.30$5.68$6.79$7.55
Low Forecast$0.32$0.13$0.41$1.86$3.11$3.71$3.58$4.76$7.08
Surprise %-65.63%92.31%-83.33%48.74%85.98%----

Revenue Forecast

$500M $1B $2B $3B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$904.40M$1.10B$1.31B$1.70B$2.07B----
Avg Forecast$891.32M$1.09B$1.27B$1.65B$2.06B$2.43B$2.86B$3.32B$3.75B
High Forecast$909.66M$1.11B$1.30B$1.69B$2.11B$2.49B$2.86B$3.35B$3.85B
Low Forecast$876.78M$1.07B$1.24B$1.64B$2.05B$2.40B$2.85B$3.28B$3.67B
Surprise %1.47%0.66%2.88%2.96%0.71%----

Net Income Forecast

$-150M $0 $150M $300M $450M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.80M$16.80M$4.60M$206.30M$418.30M----
Avg Forecast$23.92M$4.65M$-70.49M$206.30M$238.15M$289.34M$368.31M$434.07M$537.52M
High Forecast$24.56M$17.25M$-30.76M$322.59M$247.32M$316.29M$418.31M$499.77M$555.71M
Low Forecast$23.41M$-7.94M$-110.23M$90.01M$228.97M$273.53M$263.30M$350.38M$521.49M
Surprise %-71.57%261.00%-106.53%-75.65%----

PODD Forecast FAQ

Is Insulet stock a buy?

Insulet stock has a consensus rating of Buy, based on 40 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 28 Buy, 10 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Insulet is a favorable investment for most analysts.

What is Insulet's price target?

Insulet's price target, set by 40 Wall Street analysts, averages $285 over the next 12 months. The price target range spans from $270 at the low end to $300 at the high end, suggesting a potential 15.48% change from the previous closing price of $246.8.

How does Insulet stock forecast compare to its benchmarks?

Insulet's stock forecast shows a 15.48% upside, underperforming the average forecast for the healthcare stocks sector (35.94%) and underperforming the medical device stocks industry (21.01%).

What is the breakdown of analyst ratings for Insulet over the past three months?

  • April 2025: 25.00% Strong Buy, 58.33% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 21.74% Strong Buy, 60.87% Buy, 17.39% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 21.74% Strong Buy, 60.87% Buy, 17.39% Hold, 0% Sell, 0% Strong Sell.

What is Insulet’s EPS forecast?

Insulet's average annual EPS forecast for its fiscal year ending in December 2025 is $3.93, marking a -34.17% decrease from the reported $5.97 in 2024. Estimates for the following years are $4.95 in 2026, $5.96 in 2027, and $7.3 in 2028.

What is Insulet’s revenue forecast?

Insulet's average annual revenue forecast for its fiscal year ending in December 2025 is $2.43B, reflecting a 17.42% increase from the reported $2.07B in 2024. The forecast for 2026 is $2.86B, followed by $3.32B for 2027, and $3.75B for 2028.

What is Insulet’s net income forecast?

Insulet's net income forecast for the fiscal year ending in December 2025 stands at $289.34M, representing a -30.83% decrease from the reported $418.3M in 2024. Projections indicate $368.31M in 2026, $434.07M in 2027, and $537.52M in 2028.